Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CARISMA Therapeutics's book value per share for the quarter that ended in Sep. 2025 was $-0.02.
During the past 3 years, the average Book Value Per Share Growth Rate was 34.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of CARISMA Therapeutics was 34.60% per year. The lowest was 34.60% per year. And the median was 34.60% per year.
During the past 5 years, the highest P/B Ratio of CARISMA Therapeutics was 133.33. The lowest was 1.32. And the median was 3.72.
CARISMA Therapeutics (OTCPK:CARM) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
CARISMA Therapeutics Book Value per Share Related Terms
CARISMA Therapeutics Book Value per Share Historical Data
* Premium members only.
The historical data trend for CARISMA Therapeutics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARM vs SCPX, CYTOF, CNBX: Book Value per Share Comparison
For the Biotechnology subindustry, CARISMA Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARISMA Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where CARISMA Therapeutics's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics (CARM) has a Book Value per Share of $-0.02 as of Sep. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' Book Value per Share too high?
CARISMA Therapeutics' current Book Value per Share is $-0.02.
How does CARISMA Therapeutics' Book Value per Share compare to SCPX and CYTOF?
CARISMA Therapeutics' Book Value per Share of $-0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current Book Value per Share is $-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.9% below its estimated fair value. The current Book Value per Share is $-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current Book Value per Share is $-0.02 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CARM has been successfully added to your 
